Biomarkers are molecules that are used to diagnose diseases as they show whether a bodily process is normal or abnormal. Biomarkers can be any molecules, including Deoxyribonucleic Acid (DNA), proteins, or hormones, that provide information about one's health. They can be categorized based on a variety of factors, including features like imaging biomarkers or molecular biomarkers. The need for biomarkers is growing in the drug research and development process since their application boosts drug development success rates, lowers costs, and improves patient outcomes. In addition, biomarkers provide a quicker means of predicting therapeutic efficacy than traditional clinical endpoints. Biomarkers is used to study the therapeutic effect of drugs. There are different sub-types of biomarkers such as molecular, radiographic, histological and physiological. Molecular biomarkers have biophysical properties which allows to diagnosed diseases for which sample taken from patients. Radiographic biomarkers are obtained from the imaging studies. Histological and physiological biomarkers shows molecular variation in cells and tissues, and measure of body processes respectively. Prognostic biomarkers help in the detection of the cancer cells and show their progression without being affected by the treatment received. Predictive biomarkers are used to observe the response of therapy.
The Global biomarkers market is estimated to be valued at US$ 55.59 Bn in 2022 and is expected to exhibit a CAGR of 13.6% over the forecast period (2022-2030).
Figure 1: Global Biomarkers Market Share (%) Analysis, By Product Type, 2022
Global Biomarkers Market– Drivers
Increase in the numbers of research and development initiatives for improving the effectiveness of biomarkers based tests and assays is expected to boost the growth of global biomarker market over the forecast period. For instance, on March 29, 2021, FUJIFILM Wako Pure Chemical Corporation is a manufacturer of laboratory chemicals and automated laboratory solutions, announced the launch of “N501Y mutation detection kit” and “E484K mutation detection kit”. This kits are developed to detect the SARS-CoV-2 mutations.
Increase in the inorganic growth activity such as collaborations among market players is expected to drive the market growth over the forecast period. For instance, in June 2022, Nordic Bioscience and Roche Diagnostics has announced collaboration for development of biomarkers for chronic diseases. Nordic bioscience is a global player in providing biomarkers for lethal and major disease indications for pipeline required during pre-clinical and clinical development. Roche diagnostics India is a division of Roche, providing diagnostic solutions. Under this collaboration, Nordic Bioscience will transfer unique and proprietary blood-based biomarkers to Roche Diagnostics to be implemented on the automated COBAS platform. Nordic bioscience’s extracellular matrix proteins (ECM) biomarkers are used for diagnosis of all chronic diseases.
Global Biomarkers Market- Impact of the Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020. The COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regard to the transportation of drugs from one place to another.
The outbreak of COVID-19 has boosted the need of new developments in the biomarkers for better prevention, diagnostic and treatment methods. For instance, an article published by National Center for Biotechnology Information (NCBI) on August 1, 2020, when checking a patient with COVID 19, clinicians found that biomarkers were crucial in starting the treatment and a direct monitoring. This study was based on the reported data which have pre-defined outcomes. This study was done in order to estimate the relation between biomarkers and severity of COVID- 19 outcomes.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 55.59 Bn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 13.6% | 2030 Value Projection: |
US$ 154.19 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Acobiom, Apis Assay Technologies Ltd., Eagle Biosciences, Inc., Beckman Coulter, Inc., PerkinElmer Inc., Biopanda Reagents Ltd, Quanterix, Secure Diagnostics Pvt. Ltd., BioVision Inc., Merck KGaA, R&D Systems, Life Diagnostics, QuantaMatrix Inc., Nanjing Synthgene Medical Technology Co., Ltd, LifeSpan BioSciences, Inc, Wako USA, BioLegend, Inc, Abnova Corporation, and Abbexa |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Biomarkers Market – Restraints
Product recall by market players or regulatory authorities might hamper the growth of global biomarkers market over the forecast period. For instance, on September 01, 2021, Meridian Bioscience is a life science company developing, manufacturing, marketing and distributing various range of diagnostic products. Meridian Bioscience voluntarily recalled its lead care test kits. This kits were recalled due to the "Low-Control” and the "High-Control" control tests were reported to have produced "low" results by Magellan, is a subsidiary of Meridian Bioscience. The affected Lead Care Test Kit batches can understate blood lead levels when processing patient blood samples therefore Magellan started the recall.
Global Biomarkers Market – Regional Analysis
On the basis of region, the global biomarkers market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America is expected to hold a dominant position in the global biomarkers market during the forecast period owing to increasing product designations by regulatory authorities. For instance, on September 1, 2022, U.S. FDA granted a breakthrough device designation to Roche’s Elecsys Amyloid Plasma panel, which is a blood based Alzheimer’s test. This panel helps healthcare professionals to detect Alzheimer’s at an early stage.
Figure 2: Global Biomarker Market Value (US$ Bn), by Region, 2022
Global Biomarkers Market – Competitive Landscape
Major players operating in the global biomarkers market include Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Acobiom, Apis Assay Technologies Ltd., Eagle Biosciences, Inc., Beckman Coulter, Inc., PerkinElmer Inc., Biopanda Reagents Ltd, Quanterix, Secure Diagnostics Pvt. Ltd., BioVision Inc., Merck KGaA, R&D Systems, Life Diagnostics, QuantaMatrix Inc., Nanjing Synthgene Medical Technology Co., Ltd, LifeSpan BioSciences, Inc., Wako USA, BioLegend, Inc., Abnova Corporation, and Abbexa
A biomarker is a quantifiable sign of a biological condition or state. In order to investigate typical biological processes, pathogenic processes, or pharmacologic reactions to a therapeutic intervention, biomarkers are frequently examined and studied utilizing blood, urine, or soft tissues. Numerous scientific disciplines employ biomarkers. There are 2 types of biomarkers actively used in the market, they are Biomarker test Kits and Biomarker Analyzer. A relatively new set of clinical toolsets organized by clinical applications includes biomarkers utilized in the medical industry.
Market Dynamics
Increasing product launch by market players is expected to drive the market growth over the forecast period. For instance, on April 19, 2021, Amgen Inc., a global biotechnology company that uses science and innovation to translate novel concepts and medical discoveries into treatments for patients with life-threatening illnesses, announced the launch of the Biomarker Assist program, which aims to provide access to biomarker testing for patients with metastatic (stage IV) non-small cell lung cancer (NSCLC). A crucial initial step in placing patients on the appropriate course of treatment is biomarker testing at the time of diagnosis. Eligible patients may receive discounts on biomarker testing through Biomarker Assist.
Furthermore, on February 28, 2022, an initiative program was launched by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium aims to find the most effective blood tests for assessing a protein that is crucial for the early detection of rare neurodegenerative illnesses. The "Neurofilament as a Fluid Biomarker of Neuro degeneration in Familial Front temporal Degeneration (FTD)" study will demonstrate that one or more blood tests for this protein, known as neurofilament, can be used to determine individuals at risk of Front temporal Degeneration (FTD) due to genetic and familial ties. This is a crucial first step in developing a trustworthy, affordable, and non-invasive method to more accurately predict Front temporal Degeneration (FTD). Also, those who are at threat can take part in clinical studies of novel specifics, eventually leading to the development of treatments.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients